Browse Studies — Arctuva

Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol

Background: \- Lab studies help researchers better understand cancer biology. This information may lead to new methods for diagnosing or treating cancer. To d…

Hodgkin DiseaseLymphoma, Non-HodgkinMultiple Myeloma+2 more

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT01676805

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

Background: Cancer has a major impact in the United States and across the world. In 2015, over 1.5 million new cases of cancer were diagnosed in the U.S. Rese…

Multiple MyelomaLymphoma, Non-HodgkinLeukemia-Lymphoma, Adult T-Cell+2 more

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT02682667

Phase 1

A Phase I Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of Anti-CD30 Bispecific Antibody-Armed Anti-CD3-Activated Autologous T-Cells (CD30 biAb-AATC) in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

This first-in-human trial will assess the safety, feasibility, and efficacy of an immunotherapy with a novel CD30 antibody conjugated to a CD3 antibody that is…

Hodgkin DiseaseCD30-Positive Diffuse Large B-Cell LymphomaCD30+ Anaplastic Large Cell Lymphoma+4 more

Estimated

~$10 – $6,250

Medical College of WisconsinNCT05544968

Phase 2

A Phase II Trial of JAK Inhibitor Added to Immunotherapy for Treatment of Relapsed/Refractory T-cell Lymphoma and 9p Amplified Lymphomas

The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractor…

Non-Hodgkin LymphomaHodgkin Disease LymphomaNon-Hodgkin Lymphoma Refractory/ Relapsed+5 more

Estimated

~$10 – $7,500

Seda S. ToluNCT07283822